stockportfolio.pro
Lexicon Pharmaceuticals, Inc. (LXRX)
Healthcare · Biotechnology · NasdaqCM
Lexicon Pharmaceuticals, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $79.26M | $91.69M | $63.21M | $322.07M | $24.00M | $298,000 | $139,000 | $1.20M | $31.08M | $49.80M |
| Gross profit | — | $89.79M | $60.72M | $318.84M | $22.07M | — | $139,000 | $1.12M | $30.46M | $49.53M |
| Net income | $-131.44M | $-122.99M | $-120.55M | $130.13M | $-58.57M | $-87.76M | $-101.94M | $-177.12M | $-200.40M | $-50.34M |
| Net margin | -165.8% | -134.1% | -190.7% | 40.4% | -244.1% | -29449.0% | -73341.0% | -14710.9% | -644.8% | -101.1% |
Source: Lexicon Pharmaceuticals, Inc. SEC filings (10-K). 17 years of history available in the interactive view.
Explore 17 years of Lexicon Pharmaceuticals, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track LXRX in your portfolio →
Lexicon Pharmaceuticals, Inc. financial history by metric
About Lexicon Pharmaceuticals, Inc.
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes INPEFA (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, CKD, and other cardiovascular risk factors. In addition, the company develops LX9851, an orally-delivered small molecule drug candidate for the treatment of obesity and associated cardiometabolic disorders, and pilavapadin (LX9211), an orally-delivered small molecule drug candidate for the treatment of neuropathic pain. It has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Lexicon Pharmaceuticals, Inc. — frequently asked questions
What is Lexicon Pharmaceuticals, Inc.'s revenue?
Lexicon Pharmaceuticals, Inc. (LXRX) reported revenue of $49.80M for fiscal year 2025, up 60.2% from the prior year, according to its SEC filings.
Is Lexicon Pharmaceuticals, Inc. profitable?
No — LXRX reported a net loss of $-50.34M in fiscal 2025.
What is LXRX's P/E ratio?
Lexicon Pharmaceuticals, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Lexicon Pharmaceuticals, Inc. growing?
LXRX's revenue grew at roughly 15.7% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Lexicon Pharmaceuticals, Inc. have?
As of fiscal year 2025, LXRX carried roughly $54.00M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Lexicon Pharmaceuticals, Inc.'s gross margin?
LXRX's gross margin was 99.4% in fiscal 2025 — gross profit of $49.53M on revenue of $49.80M.
What is Lexicon Pharmaceuticals, Inc.'s market cap?
Lexicon Pharmaceuticals, Inc. (LXRX) has a market capitalization of about $835.09M, based on the latest data in our nightly-refreshed cache.
When does Lexicon Pharmaceuticals, Inc.'s fiscal year end?
LXRX's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Lexicon Pharmaceuticals, Inc.'s official SEC filings (10-K and 10-Q), covering 17 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.